SCHEMBL131599

SCHEMBL131599

O=C(C=Cc1ccccc1)c1ccc(O)c(O)c1O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 1/20 0.69
MAPT P10636 6/20 0.67
BCHE P06276 2/20 0.67
CYP2C19 P33261 1/20 0.67
ABCG2 Q9UNQ0 2/20 0.65
CYP1B1 Q16678 2/20 0.65
KDM4E B2RXH2 2/20 0.64
MEN1 O00255 2/20 0.64
ALDH1A1 P00352 2/20 0.64
CYP3A4 P08684 2/20 0.64
HPGD P15428 2/20 0.64
ALOX15 P16050 2/20 0.64
MAPK1 P28482 2/20 0.64
KMT2A Q03164 2/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
TDP1 Q9NUW8 2/20 0.64
THRB P10828 1/20 0.64
HSD17B10 Q99714 1/20 0.64
GUSB P08236 1/20 0.64
MAOB P27338 3/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL634100 1.00 TERT (0.69) TERTMAPTBCHECYP2C19ABCG2
SCHEMBL27579527 0.90 MAPT (0.77) MAPTBCHECYP2C19ABCG2CYP1B1
SCHEMBL27497473 0.85 MAPT (0.65) TERTMAPTBCHECYP2C19ABCG2
SCHEMBL30736439 0.84 TERT (0.70) TERTMAPTABCG2KDM4EMEN1
SCHEMBL2541146 0.84 TERT (0.70) TERTMAPTABCG2KDM4EMEN1
SCHEMBL2541144 0.84 TERT (0.70) TERTMAPTABCG2KDM4EMEN1
SCHEMBL31436349 0.84 TERT (0.70) TERTMAPTABCG2KDM4EMEN1
SCHEMBL17975287 0.83 NFE2L2 (0.63) MAPTBCHECYP2C19ABCG2CYP1B1
SCHEMBL31436357 0.83 TERT (0.69) TERTMAPTCYP2C19ABCG2CYP1B1
SCHEMBL31436334 0.83 TERT (0.69) TERTMAPTCYP2C19CYP1B1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190008797-A1 ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-01-10 US claimed
CN-101143861-A B ring 4'-single substituted flavone compounds, preparation method and use SHANGHAI INST MATERIA MEDICA (CN) 2008-03-19 CN claimed
WO-1998027970-A2 TREATMENT OF DISEASES OR PREVENTION OF CELLULAR DAMAGE CAUSED BY OXYGEN-CONTAINING FREE RADICALS NATIONAL RESEARCH COUNCIL OF CANADA (CA) 1998-07-02 WO claimed
US-20260033492-A1 Pest Repellents and Uses Thereof SENSORYGEN INC (US) 2026-02-05 US disclosed
US-20250228795-A1 ESTROGENIC COMPOUNDS AND METHODS OF USE IATERION, INC. 2025-07-17 US disclosed
EP-4561560-A1 ESTROGENIC COMPOUNDS AND METHODS OF USE Iaterion, Inc. (US) 2025-06-04 EP disclosed
US-12280129-B2 Compositions and methods for improved skin care PINSKY MARK A (US) 2025-04-22 US disclosed
WO-2024026034-A1 ESTROGENIC COMPOUNDS AND METHODS OF USE IATERION, INC. (US) 2024-02-01 WO disclosed
US-20230292754-A1 Pest Repellents and Uses Thereof UNIVERSITY OF CALIFORNIA RIVERSIDE 2023-09-21 US disclosed
US-20220117863-A1 COMPOSITIONS AND METHODS FOR IMPROVED SKIN CARE PINSKY MARK A (US) 2022-04-21 US disclosed
US-20210338558-A1 USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN FABIUS BIOTECHNOLOGY (US) 2021-11-04 US disclosed
WO-2000062743-A2 SKIN CARE COMPOSITIONS CONTAINING COMBINATION OF SKIN CARE ACTIVES THE PROCTER & GAMBLE COMPANY (US) 2000-10-26 WO disclosed
WO-2000062742-A2 METHODS FOR REGULATING THE CONDITION OF MAMMALIAN KERATINOUS TISSUE THE PROCTER & GAMBLE COMPANY (US) 2000-10-26 WO disclosed
WO-2000062745-A2 SKIN CARE COMPOSITIONS CONTAINING COMBINATION OF SKIN CARE ACTIVES THE PROCTER & GAMBLE COMPANY (US) 2000-10-26 WO disclosed
WO-2000062741-A2 SKIN CARE COMPOSITIONS CONTAINING COMBINATION OF SKIN CARE ACTIVES THE PROCTER & GAMBLE COMPANY (US) 2000-10-26 WO disclosed
US-6093411-A AN EMULSION COMPRISING FLAVONOIDS FOR PREVENTING OR TREATING SKIN DISORDERS THE PROCTER & GAMBLE COMPANY (US) 2000-07-25 US disclosed
US-6051602-A METHODS FOR PREVENTION OR TREATING SKIN DISORDERS USING FLAVONOID COMPOUNDS THE PROCTER & GAMBLE COMPANY (US) 2000-04-18 US disclosed
WO-1999047118-A1 COMPOSITIONS FOR REGULATING SKIN APPEARANCE THE PROCTER & GAMBLE COMPANY (US) 1999-09-23 WO disclosed
WO-1999047113-A1 COMPOSITIONS FOR REGULATING SKIN APPEARANCE THE PROCTER & GAMBLE COMPANY (US) 1999-09-23 WO disclosed
WO-1999047119-A1 METHODS FOR REGULATING SKIN APPEARANCE THE PROCTER & GAMBLE COMPANY (US) 1999-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210338558-A1 USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN COL14A1, COL2A1, COL1A1 TERT 4123/4885MAPT 1503/4885BCHE 2640/4885
US-20190008797-A1 ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF ESRRG, GPER1, ESR2 TERT 4625/4885MAPT 4210/4885BCHE 948/4885
US-20260033492-A1 Pest Repellents and Uses Thereof F3, TFPI, FLI1 TERT 57/4885MAPT 122/4885BCHE 641/4885
US-20250228795-A1 ESTROGENIC COMPOUNDS AND METHODS OF USE ESR1, ESR2, CYP19A1 TERT 3056/4885MAPT 2361/4885BCHE 762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.